The first 30 years of p53: growing ever more complex.

WAF1, a potential mediator of p53 tumor suppression

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138

The retinoblastoma protein and cell cycle control

Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506

Tumor suppressor p53 is a direct transcriptional activator of the human bax gene

Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53

Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia

Yan, B., Chen, Q., Xu, J., Li, W., Xu, B., & Qiu, Y. (2020) · Leukemia · doi:10.1038/s41375-020-0710-7 · Cited by 34

Identification and Validation of Six Autophagy-related Long Non-coding RNAs as Prognostic Signature in Colorectal Cancer

Cheng, L., Han, T., Zhang, Z., Yi, P., Zhang, C., Zhang, S., & Peng, W. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.49449 · Cited by 35

Protein detection in blood with single-molecule imaging

Mao, C.-P., Wang, S.-C., Su, Y., Tseng, S.-H., He, L., Wu, A. A., Roden, R. B. S., Xiao, J., & Hung, C. (2021) · Science Advances · doi:10.1126/sciadv.abg6522 · Cited by 34

p53 dynamics upon response element recognition explored by molecular simulations

Terakawa, T., & Takada, S. (2015) · Scientific Reports · doi:10.1038/srep17107 · Cited by 34

The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants.

Miller, M., Shirole, N. H., Tian, R., Pal, D., & Sordella, R. (2016) · PubMed · Cited by 35

DNA damage‐induced cellular senescence is regulated by 53BP1 accumulation in the nuclear foci and phase separation

Oda, T., Gotoh, N., Kasamatsu, T., Handa, H., Saitoh, T., & Sasaki, N. (2023) · Cell Proliferation · doi:10.1111/cpr.13398 · Cited by 33

p53 and Myofibroblast Apoptosis in Organ Fibrosis

McElhinney, K., Irnaten, M., & O'Brien, C. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076737 · Cited by 37

Targeting mutant p53 stabilization for cancer therapy

Wang, J., Liu, W., Zhang, L., & Zhang, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1215995 · Cited by 39

Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens

Alaseem, A. M. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101790 · Cited by 36

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells

Mueller, J., Schimmer, R. R., Koch, C., Schneiter, F., Fullin, J., Lysenko, V., Pellegrino, C. E., Klemm, N., Russkamp, N. F., Myburgh, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00024-2 · Cited by 33

Risk factors for pterygium: Latest research progress on major pathogenesis

Ding, P., Wang, R., & He, Y. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109900 · Cited by 42

The 26S proteasome and initiation of gene transcription.

Durairaj, G., & Kaiser, P. (2014) · Biomolecules · doi:10.3390/biom4030827 · Cited by 34

TP53Mutation, Epithelial-Mesenchymal Transition, and Stemlike Features in Breast Cancer Subtypes

Coradini, D., Fornili, M., Ambrogi, F., Boracchi, P., & Biganzoli, E. M. (2012) · BioMed Research International · doi:10.1155/2012/254085 · Cited by 34

Loss of p53 Enhances NF-κB-Dependent Lamellipodia Formation

Guo, A. K., Hou, Y.-Y., Hirata, H., Yamauchi, S., Yip, A. K., Chiam, K., Tanaka, N., Sawada, Y., & Kawauchi, K. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24505 · Cited by 34

Chemical Variations on the p53 Reactivation Theme

Ribeiro, C. J. A., Rodrigues, C. M. P., Moreira, R., & Santos, M. M. M. (2016) · Pharmaceuticals · doi:10.3390/ph9020025 · Cited by 37

KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage

Castellini, L., Moon, E. J., Razorenova, O. V., Krieg, A. J., von Eyben, R., & Giaccia, A. J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1281 · Cited by 35

CMA down-regulates p53 expression through degradation of HMGB1 protein to inhibit irradiation-triggered apoptosis in hepatocellular carcinoma

Wu, J., Guo, J., Shi, J., Wang, H., Li, L., Guo, B., Liu, D.-X., Cao, Q., & Yuan, Z. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i13.2308 · Cited by 34

Dihydroartemisinin inhibits the tumorigenesis and invasion of gastric cancer by regulating STAT1/KDR/MMP9 and P53/BCL2L1/CASP3/7 pathways

Liang, R., Chen, W., Chen, X., Fan, H., Zhang, J., & Zhu, J. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153318 · Cited by 34

Tumor suppressor p53 regulates intestinal type 2 immunity

Chang, C., Wang, J., Zhao, Y., Liu, J., Yang, X. F., Yue, X., Wang, H., Zhou, F., Inclan-Rico, J. M., Ponessa, J. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23587-x · Cited by 35

Nucleoside diphosphate kinase Nm23-H1 regulates chromosomal stability by activating the GTPase dynamin during cytokinesis

Conery, A. R., Sever, S., & Harlow, E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010633107 · Cited by 34

The variation game: Cracking complex genetic disorders with NGS and omics data

Cui, H., Dhroso, A., Johnson, N. T., & Korkin, D. (2015) · Methods · doi:10.1016/j.ymeth.2015.04.018 · Cited by 36

Influenza A Viruses Control Expression of Proviral Human p53 Isoforms p53β and Δ133p53α

Terrier, O., Marcel, V., Cartet, G., Lane, D. P., Lina, B., Rosa‐Calatrava, M., & Bourdon, J. (2012) · Journal of Virology · doi:10.1128/jvi.07143-11 · Cited by 34

Molecular and cellular processes underlying the hallmarks of head and neck cancer

Bernstein, J. M., Bernstein, C. R., West, C., & Homer, J. J. (2012) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-012-2323-x · Cited by 34

A Novel Function of p53

Lei, H., Rhéaume, M., Cui, J. Z., Mukai, S., Maberley, D., Samad, A., Matsubara, J. A., & Kazlauskas, A. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.05.036 · Cited by 34

The Role of p53 in Determining Mitochondrial Adaptations to Endurance Training in Skeletal Muscle

Beyfuss, K. A., Erlich, A. T., Triolo, M., & Hood, D. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-32887-0 · Cited by 35

Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer

Zienolddiny, S., & Skaug, V. (2011) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s13256 · Cited by 33

p53 and Risk of Endometriosis in Indian Women

Govatati, S., Chakravarty, B., Deenadayal, M., Kodati, V. L., Manolla, M. L., Sisinthy, S., & Bhanoori, M. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0295 · Cited by 33

Is p53 the Long-Sought Molecular Trigger for Cyclophilin D–Regulated Mitochondrial Permeability Transition Pore Formation and Necrosis?

Karch, J. M., & Molkentin, J. D. (2012) · Circulation Research · doi:10.1161/circresaha.112.280990 · Cited by 33

Anti-Tumor Effects of the Polysaccharide Isolated from Tarphochlamys Affinis in H22 Tumor-Bearing Mice

Tang, X., Huang, J., Xiong, H., Zhang, K., Chen, C., Wei, X., Xu, X., Xie, Q., & Huang, R. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447811 · Cited by 33

Neomorphic mutations create therapeutic challenges in cancer

Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 33

MYC, Cell Competition, and Cell Death in Cancer: The Inseparable Triad

Giacomo, S. D., Sollazzo, M., Paglia, S., & Grifoni, D. (2017) · Genes · doi:10.3390/genes8040120 · Cited by 36

Friend or Foe: MicroRNAs in the p53 network

Luo, Z., Cui, R., Tili, E., & Croce, C. M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.013 · Cited by 34

RRAD, IL4I1, CDKN1A, and SERPINE1 genes are potentially co-regulated by NF-κB and p53 transcription factors in cells exposed to high doses of ionizing radiation

Szołtysek, K., Janus, P., Zając, G., Stokowy, T., Walaszczyk, A., Widłak, W., Wojtaś, B., Gielniewski, B., Cockell, S., Perkins, N. D., et al. (2018) · BMC Genomics · doi:10.1186/s12864-018-5211-y · Cited by 35

Methods for Discovering and Targeting Druggable Protein-Protein Interfaces and Their Application to Repurposing

Özdemir, E. S., Halakou, F., Nussinov, R., Gürsoy, A., & Keskin, Ö. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8955-3_1 · Cited by 34

Crosstalk between P53 and DNA damage response in ageing

Mohammadzadeh, A., Mirza‐Aghazadeh‐Attari, M., Hallaj, S., Saei, A. A., Alivand, M. R., Valizadeh, A., Yousefi, B., & Majidinia, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.05.004 · Cited by 34

In vivo modeling of metastatic human high-grade serous ovarian cancer in mice

Kim, O., Park, E. Y., Klinkebiel, D. L., Pack, S., Shin, Y.-H., Abdullaev, Z., Emerson, R. E., Coffey, D. M., Kwon, S. Y., Creighton, C. J., et al. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008808 · Cited by 34

Antiviral immunity and nucleic acid sensing in haematopoietic stem cell gene engineering

Piras, F., & Kajaste‐Rudnitski, A. (2020) · Gene Therapy · doi:10.1038/s41434-020-0175-3 · Cited by 32

Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies

Ezzat, K., Sturchio, A., & Espay, A. J. (2022) · Biology · doi:10.3390/biology11040535 · Cited by 34

MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity

Chinnam, M., Xu, C., Lama, R., Zhang, X., Cedeno, C. D., Wang, Y., Stablewski, A. B., Goodrich, D. W., & Wang, X. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010171 · Cited by 35

Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe

Asl, E. R., Rostamzadeh, D., Duijf, P. H. G., Mafi, S., Mansoori, B., Barati, S., Cho, W. C. S., & Mansoori, B. (2023) · Life Sciences · doi:10.1016/j.lfs.2022.121361 · Cited by 38

p53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1

Nam, S. Y., & Sabapathy, K. (2011) · Oncogene · doi:10.1038/onc.2011.150 · Cited by 33

Rlip depletion prevents spontaneous neoplasia in TP53 null mice

Awasthi, S., Tompkins, J., Singhal, J., Riggs, A. D., Yadav, S., Wu, X., Singh, S., Warden, C., Liu, Z., Wang, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719586115 · Cited by 33

Dihydroartemisinin potentiates antitumor activity of 5-fluorouracil against a resistant colorectal cancer cell line

Yao, Z., Bhandari, A., Wang, Y., Pan, Y., Yang, F., Chen, R., Xia, E., & Wang, O. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.026 · Cited by 33

Nuclear iASPP may facilitate prostate cancer progression

Morris, E. V., Cerundolo, L., Lu, M. M., Verrill, C. L., Fritzsche, F., White, M. J., Thalmann, G. N., ten Donkelaar, C. S., Ratnayaka, I., Salter, V., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.442 · Cited by 32

RNF38 encodes a nuclear ubiquitin protein ligase that modifies p53

Sheren, J. E., & Kassenbrock, C. K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.08.031 · Cited by 32

Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy

Yamaguchi, F., Kugawa, S., Tateno, H., Kokubu, F., & Fukuchi, K. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.08.014 · Cited by 33

Spirooxadiazoline oxindoles with promising in vitro antitumor activities

Ribeiro, C. J. A., Amaral, J. D., Rodrigues, C. M. P., Moreira, R., & Santos, M. M. M. (2015) · MedChemComm · doi:10.1039/c5md00450k · Cited by 32

Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway

Zhanfeng, N., Chengquan, W., Hechun, X., Jun, W., Lijian, Z., Ma, D., Wenbin, L., & Lei, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8439 · Cited by 33

Prognostic significance of p53 expression in patients with esophageal cancer: a meta-analysis

Wang, L., Yu, X., Li, J., Zhang, Z., Hou, J., & Li, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2427-6 · Cited by 32

Vitamin�D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model

Maj, E., Filip‐Psurska, B., Milczarek, M., Psurski, M., Kutner, A., & Wietrzyk, J. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4228 · Cited by 32

p53 balances between tissue hierarchy and anarchy

Koifman, G., Aloni-Grinstein, R., & Rotter, V. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz022 · Cited by 33

Regenerative and protective effects of calcium silicate on senescent fibroblasts induced by high glucose

Li, B., Bian, X., Hu, W., Wang, X., Li, Q., Wang, F., Sun, M., Ma, K., Zhang, C., Chang, J., et al. (2020) · Wound Repair and Regeneration · doi:10.1111/wrr.12794 · Cited by 32

IGFBP-3 Blocks Hyaluronan-CD44 Signaling, Leading to Increased Acetylcholinesterase Levels in A549 Cell Media and Apoptosis in a p53-Dependent Manner

Price, D., Muterspaugh, R., Clegg, B., Williams, A., Stephens, A., Guthrie, J. W., Heyl, D., & Evans, H. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-61743-3 · Cited by 32

Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer

Montagna, M. L., GINN, L. H., & Garofalo, M. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00214-3 · Cited by 32

Tumor suppressor protein p53 expressed in yeast can remain diffuse, form a prion, or form unstable liquid-like droplets

Park, S.-K., Park, S., Pentek, C., & Liebman, S. W. (2020) · iScience · doi:10.1016/j.isci.2020.102000 · Cited by 35

Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy

Saleh, A., & Perets, R. (2021) · Cancers · doi:10.3390/cancers13143465 · Cited by 33

Targeting ERK induced cell death and p53/ROS-dependent protective autophagy in colorectal cancer

Mi, W., Wang, C., Luo, G., Li, J., Zhang, Y., Jiang, M., Zhang, C., Liu, N., Jiang, X., Yang, G., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00677-9 · Cited by 34

Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism?

Hu, J., Liu, Z., & Wang, X. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.06.009 · Cited by 33

Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks

Li, X. L., Jones, M. F., Subramanian, M., & Lal, A. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.054 · Cited by 33

Pioneering the future of cancer therapy: Deciphering the p53-ferroptosis nexus for precision medicine

Shin, D., Lee, J., & Roh, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216645 · Cited by 33

Influence of P53 on the radiotherapy response of hepatocellular carcinoma

Gomes, A. R., Abrantes, A. M., Brito, A., Laranjo, M., Casalta‐Lopes, J., Gonçalves, A. C., Sarmento‐Ribeiro, A. B., Botelho, M. F., & Tralhão, J. G. (2015) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2015.21.3.257 · Cited by 31

Purified essential oil from Ocimum sanctum Linn. triggers the apoptotic mechanism in human breast cancer cells

Thirugnanasampandan, R., Manaharan, T., Rajarajeswaran, J., Kanthimathi, M. S., Ramya, G., & Ramnath, M. G. (2016) · Pharmacognosy Magazine · doi:10.4103/0973-1296.185738 · Cited by 31

Are Neuroendocrine Negative Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma with WT RB1 two Faces of the Same Entity?

Sonkin, D., Thomas, A., & Teicher, B. A. (2019) · Lung Cancer Management · doi:10.2217/lmt-2019-0005 · Cited by 31

P53 Mutant p53N236S Regulates Cancer-Associated Fibroblasts Properties Through Stat3 Pathway

Liu, Q., Yu, B., Tian, Y., Dan, J., Luo, Y., & Wu, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s229065 · Cited by 31

Reactivation of Epstein-Barr Virus by HIF-1α Requires p53

Kraus, R. J., Cordes, B.-L. A., Sathiamoorthi, S., Patel, P., Yuan, X., Iempridee, T., Yu, X., Lee, D. L., Lambert, P. F., & Mertz, J. E. (2020) · Journal of Virology · doi:10.1128/jvi.00722-20 · Cited by 32

Distinct mechanisms control genome recognition by p53 at its target genes linked to different cell fates

Farkaš, M., Hashimoto, H., Bi, Y., Davuluri, R. V., Resnick‐Silverman, L., Manfredi, J. J., Debler, E., & McMahon, S. B. (2021) · Nature Communications · doi:10.1038/s41467-020-20783-z · Cited by 31

Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer

Souza, C. D., Madden, J. A., Koestler, D. C., Minn, D., Montoya, D. J., Minn, K. T., Raetz, A. G., Zhu, Z. G., Xiao, W.-W., Tahmassebi, N., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab019 · Cited by 31

Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity

Isermann, T., Sener, Ö. C., Stender, A., Klemke, L., Winkler, N., Neeße, A., Li, J., Wegwitz, F., Moll, U. M., & Schulz‐Heddergott, R. (2021) · Nature Communications · doi:10.1038/s41467-021-24064-1 · Cited by 31

Transcriptome Analysis of Pterygium and Pinguecula Reveals Evidence of Genomic Instability Associated with Chronic Inflammation

Suárez, M. F., Echenique, J., López, J. M., Medina, E., Irós, M., Serra, H. M., & Fini, M. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112090 · Cited by 31

Crosstalk between lncRNAs in the apoptotic pathway and therapeutic targets in cancer

Ebrahimi, N., Parkhideh, S., Samizade, S., Esfahani, A. N., Samsami, S., Yazdani, E., Adelian, S., Chaleshtori, S. R., Shahamiri, K., Ahmadi, A., et al. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.04.003 · Cited by 31

Biphasic JNK-Erk signaling separates the induction and maintenance of cell senescence after DNA damage induced by topoisomerase II inhibition

Netterfield, T. S., Ostheimer, G. J., Tentner, A. R., Joughin, B. A., Dakoyannis, A. M., Sharma, C. D., Sorger, P. K., Janes, K. A., Lauffenburger, D. A., & Yaffe, M. B. (2022) · Cell Systems · doi:10.1016/j.cels.2023.06.005 · Cited by 32

DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats

Hx, Y., Wu, H.-P., Hl, Z., Ashton, C., Tong, C., Wu, J., Qian, Q.-J., Wang, H.-Y., & Ql, Y. (2012) · Oncogene · doi:10.1038/onc.2012.451 · Cited by 32

Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis

Zane, L. K., Yasunaga, J., Mitagami, Y., Yedavalli, V. R. K., Tang, S.-W., Chen, C., Ratner, L., Lu, X., & Jeang, K.-T. (2012) · Retrovirology · doi:10.1186/1742-4690-9-114 · Cited by 34

The Role of p53 in Combination Radioimmunotherapy with 64Cu-DOTA-Cetuximab and Cisplatin in a Mouse Model of Colorectal Cancer

Guo, Y., Parry, J. J., Laforest, R. A., Rogers, B. E., & Anderson, C. J. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.118539 · Cited by 31

Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade

Yen, C.-S., Chen, J., Chang, Y.-F., Hsu, Y.-F., Chiu, P.-T., Shiue, C., Chuang, Y., Ou, G., & Hsu, M. (2016) · Scientific Reports · doi:10.1038/srep25082 · Cited by 31

PEPD is a pivotal regulator of p53 tumor suppressor

Yang, L., Li, Y., Bhattacharya, A., & Zhang, Y. (2017) · Nature Communications · doi:10.1038/s41467-017-02097-9 · Cited by 33

IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes

Christgen, M., Noskowicz, M., Heil, C., Schipper, E., Christgen, H., Geffers, R., Kreipe, H. H., & Lehmann, U. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.126 · Cited by 31

Resistance acquisition to MDM2 inhibitors

Cinatl, J., Speidel, D., Hardcastle, I., & Michaelis, M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140035 · Cited by 30

MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation

Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30

Expression of MYSM1 is associated with tumor progression in colorectal cancer

Li, Y., Li, J., He, L., Liu, Y., & Cui, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177235 · Cited by 30

Dysregulation of the mTOR pathway in p53-deficient mice

Leontieva, O. V., Novototskaya, L. R., Paszkiewicz, G., Komarova, E. A., Gudkov, A. V., & Blagosklonny, M. V. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26947 · Cited by 30

Stochastic and Deterministic Models of Cellular p53 Regulation

Leenders, G. B., & Tuszyński, J. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00064 · Cited by 28

Identification and Characterization of MicroRNAs by High Through-Put Sequencing in Mesenchymal Stem Cells and Bone Tissue from Mice of Age-Related Osteoporosis

He, X., Zhang, W., Liao, L., Fu, X., Yu, Q., & Jin, Y. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071895 · Cited by 29

Regulation of the MDM2-p53 pathway by the nucleolar protein CSIG in response to nucleolar stress

Xie, N., Ma, L., Zhu, F., Zhao, W., Tian, F., Yuan, F., Fu, J., Huang, D., Lv, C., & Tong, T. (2016) · Scientific Reports · doi:10.1038/srep36171 · Cited by 31

Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status

de Oliveira, D. T., Sávio, A. L. V., Marcondes, J. P. D. C., Barros, T. M. B., Barbosa, L. C., Salvadori, D. M. F., & da Silva, G. N. (2016) · Journal of Biosciences · doi:10.1007/s12038-016-9654-5 · Cited by 30

Efficient generation of P53 biallelic knockout Diannan miniature pigs via TALENs and somatic cell nuclear transfer

Shen, Y., Xu, K., Yuan, Z., Guo, J., Zhao, H., Zhang, X., Zhao, L., Qing, Y., Li, H., Pan, W., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1327-0 · Cited by 30

Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers?

Kuguyo, O., Tsikai, N., Thomford, N. E., Magwali, T. L., Madziyire, M. G., Nhachi, C. F. B., Matimba, A., & Dandara, C. (2018) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2018.0075 · Cited by 32

Determination of p53 biomarker using an electrochemical immunoassay based on layer-by-layer films with NiFe2O4 nanoparticles

Ibáñez-Redín, G., Joshi, N., do Nascimento, G. F., Wilson, D., Melendez, M. E., Carvalho, A. L., Reis, R. M., Gonçalves, D., & Oliveira, O. N. (2020) · Microchimica Acta · doi:10.1007/s00604-020-04594-z · Cited by 30

Therapeutic potential of p53 reactivation in cervical cancer

Zhao, X., Sun, W., Ren, Y., & Lu, Z. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103182 · Cited by 30

Novel Mouse Models for Cancer Immunology

Connolly, K. A., Fitzgerald, B., Damo, M., & Joshi, N. S. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-105523 · Cited by 31

Inflammasome Activation and Pyroptosis via a Lipid-regulated SIRT1-p53-ASC Axis in Macrophages From Male Mice and Humans

Huang, Y., Yong, P., Dickey, D. M., Vora, S. M., Wu, H., & Bernlohr, D. (2022) · Endocrinology · doi:10.1210/endocr/bqac014 · Cited by 29

p53: A Regulator of Ferroptosis Induced by Galectin-1 Derived Peptide 3 in MH7A Cells

Hu, J., Zhang, R., Chang, Q., Ji, M.-L., Zhang, H., Geng, R., Li, C., & Wang, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.920273 · Cited by 30

The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells

Wu, C., Huang, K., Yang, T., Li, Y., Wen, C.-L., Hsu, S., & Chen, T.-H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132052 · Cited by 29

Contribution of cyclin D1 (CCND1) and E-cadherin (CDH1) alterations to colorectal cancer susceptibility: a case–control study

Govatati, S., Singamsetty, G. K., Nallabelli, N., Malempati, S., Rao, P. S., Madamchetty, V. K. K., Govatati, S., Devi, K. R., Nagesh, N., Bhanoori, M., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2505-9 · Cited by 30

p53 and its mutants on the slippery road from stemness to carcinogenesis

Molchadsky, A., & Rotter, V. (2017) · Carcinogenesis · doi:10.1093/carcin/bgw092 · Cited by 30

The Power Behind the Throne: Senescence and the Hallmarks of Cancer

Hoare, M., & Narita, M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050352 · Cited by 33

A Novel Inhibitor Targets Both Wnt Signaling and ATM/p53 in Colorectal Cancer

Cheng, J., Dwyer, M., Okolotowicz, K. J., Mercola, M. A., & Cashman, J. R. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2642 · Cited by 30

Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1

Dillen, A., Bui, I., Jung, M., Agioti, S., Zaravinos, A., & Bonavida, B. (2024) · Cancers · doi:10.3390/cancers16061237 · Cited by 29

Triptolide Induces Growth Inhibition and Apoptosis of Human Laryngocarcinoma Cells by Enhancing p53 Activities and Suppressing E6-Mediated p53 Degradation

Zhao, F., Huang, W., Tamgue, O., Zhang, B., Han, Y., Clotaire, D. Z. J., Wang, C., Chang, H., Luo, H., Ren, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080784 · Cited by 30

Gain-of-function mutant p53: history and speculation

Bargonetti, J., & Prives, C. L. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz067 · Cited by 87

A comprehensive study of p53 protein

Patil, M. R., & Bihari, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30331 · Cited by 57

p53 Tumor Suppressor Protein

Ashcroft, M. A., & Vousden, K. H. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-230-2_7 · Cited by 5

Introduction: p53 – the first twenty years

Oren, M., & Rotter, V. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050265 · Cited by 141

A History of Cancer Research: The P53 Pathway.Preprint

Lipsick, J. S. (2025) · PubMed · doi:10.1101/cshperspect.a035931 · Cited by 6